Table 1 Comparisons of characteristics between survivors and non-survivors in patients with HBV-ACLF
| Variables |
Total patients (n = 421) |
Survivors (n = 222) |
Non-survivors (n = 199) | P value |
|---|---|---|---|---|
| Age (years) | 47.93 ± 11.40 | 48.10 ± 11.20 | 47.75 ± 11.64 | 0.735 |
| Gender (M/F) | 365/56 | 195/27 | 170/29 | 0.468 |
| Cirrhosis (%) | 299(71.02%) | 159(71.62) | 140(70.35) | 0.744 |
| Bacterial infections | 307(72.92%) | 145(65.32) | 162(81.41) | < 0.001 |
| HBV-DNA (107IU/mL) | 1.53 ± 4.85 | 1.89 ± 5.16 | 1.17 ± 4.53 | 0.139 |
| HbeAg(+) n (%) | 116(27.55) | 67(30.18) | 49(24.62) | 0.203 |
| ALT(U/L) | 228(63.20,847.60) | 258.75(52.65,1000.33) | 198.20(74.80,755.10) | 0.532 |
| AST(U/L) | 223.40(103.95,641.90) | 254.10(94.63,254.10) | 206.10(110.10,511.20) | 0.477 |
| TBIL(μmol/L) | 323.39 ± 165.69 | 236.35 ± 118.55 | 420.49 ± 156.77 | < 0.001 |
| ALB(g/L) | 29.09 ± 5.57 | 29.33 ± 5.81 | 28.82 ± 5.30 | 0.348 |
| γ-GGT(U/L) | 85.40(48.5143.00) | 79.35(48.45,157,13) | 86.30(48.50,126.80) | 0.719 |
| Cr (μmol/L) | 69.30(57.25,87.90) | 68.45(57.90,79.78) | 70.1(55.6106.8) | 0.002 |
| Cyst-c(mg/L) | 1.21(0.92,1.756) | 1.11(0.89,1.55) | 1.38(0.93,1.38) | 0.001 |
| K+(mmol/L) | 3.97 ± 0.65 | 3.99 ± 0.60 | 3.95 ± 0.70 | 0.510 |
| Na+(mmol/L) | 135.46 ± 5.71 | 135.79 ± 5.70 | 134.86 ± 5.66 | 0.042 |
| PT(s) | 24.90(21.35,29.30) | 23.70(21.38,27.88) | 26.40(21.3,31.7) | 0.271 |
| INR | 2.25(1.86,2.76) | 2.12(1.86,2.62) | 2.40(1.85,3.16) | < 0.001 |
| PTA (%) | 34.11 ± 10.60 | 35.79 ± 9.49 | 32.23 ± 11.45 | 0.001 |
| WBC (109/L) | 6.43(4.72,9.13) | 5.83(424,7.86) | 7.56(5.45,10.71) | < 0.001 |
| Neutrophils (109/L) | 4.65(3.11,7.21) | 3.92(2.88,5.80) | 5.98(3.82,8.52) | < 0.001 |
| Lymphocytes(109/L) | 0.96(0.66,1.33) | 1.03(0.71,1.41) | 0.89(0.61,1.28) | 0.030 |
| Monocytes(109/L) | 0.61(0.40,0.90) | 0.54(0.37,0.77) | 0.70(0.45,1.04) | < 0.001 |
| RDW (%) | 15.90(14.35,18.45) | 15.00(14.0,17.03) | 16.82(15.00,20.70) | < 0.001 |
| PLT (109/L) | 86.00 (58.0,126.0) | 82.00(53.0,125.0) | 89.00(64.0,89.0) | 0.155 |
| MPV(FL) | 11.75 ± 1.53 | 11.82 ± 1.48 | 11.67 ± 1.58 | 0.312 |
| NLR | 4.84(3.19,8.09) | 4.00(2.57,6.10) | 6.31(4.19,10.25) | < 0.001 |
| GPR | 0.97(0.59,1.69) | 0.98(0.62,1.69) | 0.95(0.51,1.70) | 0.253 |
| MLR | 0.64(0.42,0.94) | 0.53(0.38,0.74) | 0.77(0.52,1.10) | < 0.001 |
| RPR | 0.19(0.12,0.30) | 0.18(0.12,0.32) | 0.19(0.14,0.30) | 0.490 |
| MPR | 0.14(0.09,0.20) | 0.15(0.10,0.22) | 0.13(0.09,0.19) | 0.103 |
| PNI | 34.10(30.20,38.33) | 34.98(30.33,39.14) | 33.65(30.10,37.30) | 0.060 |
| PLR | 91.03(62.66,127.75) | 85.20(57.45,118.76) | 102.15(70.37,144.12) | 0.001 |
| RLR | 16.70(11.66,25.96) | 15.68(10.66,22.65) | 20.57(13.25,30.00) | < 0.001 |
| PCT (μg/L) | 0.88(0.48,3.31) | 0.79(0.44,2.88) | 0.99(0.54,3.52) | 0.064 |
| MELD SCORE | 25.05 ± 6.75 | 22.47 ± 4.67 | 27.94 ± 7.52 | < 0.001 |
| MELD-Na | 24.43 ± 12.48 | 20.36 ± 11.09 | 28.98 ± 12.41 | < 0.001 |
| CTP, n (%) | < 0.001 | |||
| 5–6 | 1(0.24) | 1(0.45) | 0(0) | |
| 7–9 | 69(16.39) | 56(25.21) | 13(6.53) | |
| ≥ 10 | 351(83.37) | 165(74.32) | 186(93.46) | |
| HE, n (%) | 0.005 | |||
| Stage 0 | 332(78.86) | 184(82.90) | 148(74.37) | |
| Stage 1 | 14(3.33) | 9(4.10) | 5(2.51) | |
| Stage 2 | 23(5.46) | 12(5.4) | 11(5.53) | |
| Stage 3 | 28(6.65) | 13(5.9) | 15(7.54) | |
| Stage 4 | 24(5.70) | 4(1.8) | 20(10.05) | |
| Antiviral therapy, n (%) | 0.841 | |||
| ETV | 339(80.52) | 175(78.83) | 164(82.41) | |
| TDF | 56(13.30) | 32(14.41) | 24(12.06) | |
| LAM | 10(2.38) | 5(2.25) | 5(2.51) | |
| ADV | 12(3.09) | 7(3.15) | 5(2.51) | |
| ADV + LAM | 4(0.95) | 3(1.35) | 1(0.50) |
